Category - Developments

Developments

NeoTX enrolls first patient in Phase 2a NAP trial in NSCLC

Closely-held NeoTX Therapeutics of Israel enrolled the first patient in its Phase 2a clinical trial of naptumomab estafenatox (NAP), its lead tumor targeted superantigen candidate, in combination with docetaxel in...

October 20, 2021

Developments

111, Inc. executive chairman Dr. YU Gang receives 2021 China Artificial Intelligence Award

Dr. YU Gang, co-founder and executive chairman of 111, Inc. (NASDAQ:YI), received the 2021 China AI Golden Goose Award for outstanding achievements. In accepting the award at the 2021 China Artificial Intelligence...

October 19, 2021

Developments

Entasis posts positive topline Phase 3 results with SUR-DUR

Entasis Therapeutics (NASDAQ:ETTX) announced positive topline results from its ATTACK global Phase 3 trial evaluating the safety and efficacy of SUL-DUR (sulbactam-durlobactam) versus colistin in patients with...

October 19, 2021

Developments

111, Inc. selected to 2021 China Top 20 Internet Healthcare Companies list

111, Inc. (NASDAQ:YI) was selected as one of the 2021 Top 20 Internet Healthcare Enterprises in China for its innovation and promotion in the internet+healthcare field and its transformative platform serving the...

October 15, 2021

Developments

VistaGen expands PH948 in Phase 2a trial for adjustment disorder

VistaGen Therapeutics (NASDAQ:VTGN) initiated a Phase 2a clinical trial to evaluate the efficacy, safety and tolerability of PH94B as a potential treatment of anxiety in adults with adjustment disorder with anxiety...

October 14, 2021

Developments

FDA accepts Altamira 510(k) application for Bentrio

Altamira Therapeutics’ (NASDAQ:CYTO) 510(k) application for premarket clearance for its Bentrio nasal spray for protection against airborne allergens was accepted for review by the FDA. The application now moves to a...

October 14, 2021

Developments

Labster to acquire UbiSim in virtual reality training expansion

Labster, a leading platform for virtual labs and interactive science based in Denmark, signed a definitive agreement to acquire UbiSim, a virtual reality training platform for nursing, in a move to further transform...

October 14, 2021

Developments

IntelGenx to resume Phase 2a patient screening with Montelukast VersaFilm in AD

IntelGenx (TSX:IGX; OTCQB:IGXT) intends to resume patient screening in the ongoing Montelukast VersaFilm Phase 2a BUENA clinical trial in patients with mild-to-moderate Alzheimer’s disease (AD) following Health Canada’s...

October 12, 2021

Developments

Titan Pharma, MUSC Foundation in research, option license agreement

Titan Pharmaceuticals (NASDAQ:TTNP) entered into a research and option license agreement with the MUSC Foundation for Research Development (MUSC FRD) and will conduct certain research, evaluation, proof-of-concept...

October 12, 2021

Developments

Supernus Pharma to acquire Adamas Pharma for $400-million plus CVRs

Supernus Pharmaceuticals (NASDAQ:SUPN) agreed to acquire Adamas Pharmaceuticals (NASDAQ:ADMS) in a tender offer for $8.10 a share in cash, or about $400-million plus two non-tradable contingent value rights (CVR). The...

October 11, 2021

Category - Developments

NeoTX enrolls first patient in Phase 2a NAP trial in NSCLC

111, Inc. executive chairman Dr. YU Gang receives 2021 China Artificial Intelligence Award

Entasis posts positive topline Phase 3 results with SUR-DUR

111, Inc. selected to 2021 China Top 20 Internet Healthcare Companies list

VistaGen expands PH948 in Phase 2a trial for adjustment disorder

FDA accepts Altamira 510(k) application for Bentrio

Labster to acquire UbiSim in virtual reality training expansion

IntelGenx to resume Phase 2a patient screening with Montelukast VersaFilm in AD

Titan Pharma, MUSC Foundation in research, option license agreement

Supernus Pharma to acquire Adamas Pharma for $400-million plus CVRs

General

More